← Back to Search

Telehealth Support for Liver Cirrhosis

N/A
Waitlist Available
Led By Vandana Khungar, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

Study Summary

This trial looks at how a telehealth intervention may help reduce hospital readmissions for cirrhotic patients. Patients will receive daily texts & weekly phone calls for 90 days. Rates & days to readmission will be compared between groups.

Who is the study for?
This trial is for cirrhosis patients at the University of Pennsylvania Hospital who can read and consent in English, have a cell phone to receive texts, or have someone who can handle communications for them. It's not for non-cirrhotic individuals, those with severe other diseases expected to be fatal within six months, without texting capability, unable to consent in English, post-liver transplant patients, or those using illicit substances.Check my eligibility
What is being tested?
The study tests if a telehealth intervention with daily texts and weekly calls after hospital discharge reduces readmissions over 90 days compared to standard care. Participants are randomly placed into two groups: one receives the telehealth follow-up; the other gets usual care.See study design
What are the potential side effects?
Since this trial involves a non-medical intervention (telehealth communication), there are no direct medical side effects associated with drugs or procedures. However, participants may experience privacy concerns or stress related to frequent communication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
A change in readmission rates of cirrhotic patients
Secondary outcome measures
A difference in patient or caregiver satisfaction post-discharge.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Daily telehealth follow-upExperimental Treatment1 Intervention
The intervention arm will receive a simple telehealth intervention utilizing the Way to Health Platform engineered at the University of Pennsylvania. This platform will be used to send daily SMS messages to patients for 90 days following discharge and alert the research team to changes in patients' status. In addition, the patients in the intervention arm will receive a weekly phone call administered by members of the research team to assess their overall progress and well-being.
Group II: Standard of care follow-upActive Control1 Intervention
Standard of care
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intervention
2011
Completed Phase 4
~73780

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,992 Previous Clinical Trials
42,875,083 Total Patients Enrolled
Vandana Khungar, MDPrincipal InvestigatorUniversity of Pennsylvania

Media Library

Telehealth Intervention Clinical Trial Eligibility Overview. Trial Name: NCT03969186 — N/A
Liver Disease Research Study Groups: Daily telehealth follow-up, Standard of care follow-up
Liver Disease Clinical Trial 2023: Telehealth Intervention Highlights & Side Effects. Trial Name: NCT03969186 — N/A
Telehealth Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT03969186 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~37 spots leftby Mar 2025